Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology Learning NetworkAddition of Induction Chemotherapy to Standard-of-Care Chemoradiation Improves Survival Outcomes in Locally Advanced Cervical Cancer

Results From the Phase 3 GCIG INTERLACE Study

The phase 3 GCIG INTERLACE study, presented by Dr. Mary McCormack at the 2023 ESMO Congress, has revealed a significant improvement in progression-free and overall survival rates among patients with advanced cervical cancer. The addition of a short course of induction chemotherapy to standard-of-care chemoradiation has been identified as a potential new standard of care.

Key Points

  • The study randomized 500 patients between standard-of-care chemoradiation and the same standard of care preceded by 6 weeks of carboplatin and paclitaxel chemotherapy.
  • There was no gap between the chemotherapy and the start of radiation.
  • In the standard-of-care arm, 64% of women were alive and free of disease at 5 years.
  • In the experimental arm with the additional chemotherapy, 74% were alive without evidence of disease recurrence at 5 years.
  • The 5-year overall survival with locally advanced disease improved from 72% to 80% with the addition of chemotherapy.

…with the additional 6 weeks of chemotherapy, we found that the 5-year survival is boosted to 80%. This is also a tremendous improvement, and it’s probably the biggest shift that we’ve seen in outcome in this disease in over 20 years.
— Mary McCormack, MD, University College London Hospital, United Kingdom

More on Cervical Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form